Evidence map›Paper›PMID 39958657›Full record

ReviewEndoscopy international open2025

On-site ERCP availability and cholangitis outcomes: Retrospective cohort study.

Rishad Khan, Kayley-Jasmin Marchena-Romero, Marwa F Ismail, Surain B Roberts, Nikko Gimpaya, Michael A Scaffidi, Nasruddin Sabrie, Kareem Khalaf, Jeffrey Mosko, Paul James and 4 more

Abstract readReview
In one paragraph

Review in Endoscopy international open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Rishad KhanDepartment of Medicine, University of Toronto, Toronto, Canada.ORCID 0000-0002-5090-7685
Kayley-Jasmin Marchena-RomeroGEMINI, St Michael's Hospital Li Ka Shing Knowledge Institute, Toronto, Canada.
Marwa F IsmailGEMINI, St Michael's Hospital Li Ka Shing Knowledge Institute, Toronto, Canada.
Surain B RobertsGEMINI, St Michael's Hospital Li Ka Shing Knowledge Institute, Toronto, Canada.
Nikko GimpayaDivision of Gastroenterology, Scarborough Health Network, Scarborough, Canada.
Michael A ScaffidiDepartment of Medicine, Queen's University, Kingston, Canada.ORCID 0000-0003-2068-6655
Nasruddin SabrieDepartment of Medicine, University of Toronto, Toronto, Canada.
Kareem KhalafDivision of Gastroenterology, St Michael's Hospital, Toronto, Canada.ORCID 0000-0002-5534-7533
Jeffrey MoskoDivision of Gastroenterology, St Michael's Hospital, Toronto, Canada.
Paul JamesMedicine, The University Health Network, Toronto, Canada.
Nauzer ForbesMedicine, University of Calgary, Calgary, Canada.
Fahad RazakDepartment of Medicine, St Michael's Hospital, Toronto, Canada.
Amol A VermaDepartment of Medicine, St Michael's Hospital, Toronto, Canada.
Samir C GroverDivision of Gastroenterology, Scarborough Health Network, Scarborough, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and study aims: Endoscopic retrograde cholangiopancreatography (ERCP) is important in acute cholangitis (AC) management but is not available at all hospitals. The association between on-site ERCP availability and cholangitis outcomes is unknown. Patients and methods: We included adults diagnosed with AC at 27 hospitals in Ontario through the GEMINI network. We collected data on demographics, clinical and laboratory values, and interventions. The primary outcome was in-hospital mortality. Secondary outcomes were length of stay, intensive care unit (ICU) admission, readmission rates, and requirement for percutaneous or surgical decompression. We used multivariable regression analyses to assess the impact of on-site ERCP availability on the primary and secondary outcomes with adjustment for relevant variables. Results: Our cohort included 4492 patients with a median age of 75. Patients at ERCP sites had higher unadjusted rates of undergoing ERCP (55.7% at ERCP sites, 40.8% at non-ERCP sites). Patients at ERCP sites compared with non-ERCP sites did not have significantly different in-hospital mortality (adjusted odds ratio [aOR] = 2.19, 95% confidence interval [CI] = 0.86-5.55). Compared with non-ERCP sites, patients at ERCP sites with underlying stricturing biliary disease or pancreaticobiliary malignancy (aOR = 1.94, 95% CI = 1.14-13.58) or severe cholangitis (aOR = 2.17, 95% CI = 1.17-4.02) had higher odds of in-hospital mortality. In a post-hoc propensity score-based analysis, there was no significant difference between patients at ERCP sites compared with those at non-ERCP sites for in-hospital mortality. Conclusions: Patients at ERCP sites compared with non-ERCP sites did not have significantly different mortality. Subgroups of patients with underlying stricturing biliary disease or pancreaticobiliary malignancy and severe cholangitis, who have higher mortality at ERCP sites, warrant further study.

Indexed as

EpidemiologyERC topicsPancreatobiliary (ERCP/PTCD)Quality and logistical aspectsQuality management

Identifiers

PMID39958657
PMCPMC11827753

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.